Amicus Therapeutics (FOLD) Soars: Stock Adds 9.2% in Session
Amicus Therapeutics, Inc. FOLD was a big mover last session, as the company saw its shares rise more than 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company — as the stock is now up 15.3% in the past one-month time frame.
The move came after the company reported additional positive results from the clinical trial of Phase 1/2 of its drugs ATB200/AT2221 in patients suffering from Pompe disease.
The company has seen a mixed track record when it comes to estimate revision of one increase and two decrease over the past few weeks, while the Zacks Consensus Estimate for the current quarter hasn’t been in a trend either. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Amicus Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Amicus Therapeutics, Inc. Price
Amicus Therapeutics, Inc. Price | Amicus Therapeutics, Inc. Quote
Investors interested in the Medical - Biomedical and Genetics industry may consider Ligand Pharmaceuticals Incorporated LGND, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is FOLD going up? Or down? Predict to see what others think:Up or Down
4 Stocks to Watch after the Massive Equifax Hack
Cybersecurity stocks spiked on recent news of a data breach affecting 143 million Americans. But which stocks are the best buy candidates right now? And what does the future hold for the cybersecurity industry?
Equifax is just the most recent victim. Computer hacking and identity theft are more common than ever. Zacks has just released Cybersecurity! An Investor’s Guide to inform Zacks.com readers about this $170 billion/year space. More importantly, it highlights 4 cybersecurity picks with strong profit potential.
Get the new Investing Guide now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report
Amicus Therapeutics, Inc. (FOLD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
